Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126385832 | 12638583 | 2 | F | 2010 | 20160801 | 20160809 | 20160824 | EXP | US-TEVA-682651USA | TEVA | 0.00 | F | Y | 0.00000 | 20160825 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126385832 | 12638583 | 1 | PS | CILOSTAZOL. | CILOSTAZOL | 1 | Oral | 200 MILLIGRAM DAILY; | UNKNOWN | 77027 | 100 | MG | TABLET | BID | |||||
| 126385832 | 12638583 | 2 | SS | PLETAL | CILOSTAZOL | 1 | Oral | 200 MILLIGRAM DAILY; | 0 | 100 | MG | TABLET | BID | ||||||
| 126385832 | 12638583 | 3 | C | SYNTHROID | LEVOTHYROXINE SODIUM | 1 | 0 | ||||||||||||
| 126385832 | 12638583 | 4 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | 0 |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126385832 | 12638583 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126385832 | 12638583 | Drug ineffective | |
| 126385832 | 12638583 | Foreign body | |
| 126385832 | 12638583 | Hip fracture | |
| 126385832 | 12638583 | Oral neoplasm |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126385832 | 12638583 | 1 | 2013 | 2013 | 0 | |
| 126385832 | 12638583 | 2 | 2006 | 2013 | 0 |